Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results